CorMedix (CRMD) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Prothena (PRTA) has outperformed CorMedix (CRMD) over the past year, losing 21.6% versus a loss of 45.6%. Over five years, CRMD leads with a +3.9% price change compared with -83.3% for PRTA. Prothena is the larger company by market cap ($422.1 million vs $419.2 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs -92.8%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -2520.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | PRTA |
|---|---|---|
| Share price | $5.27 | $8.22 |
| Market cap | $419.16M | $422.10M |
| 1-day change | +3.74% | -2.14% |
| YTD return | -54.69% | -13.93% |
| 1-year return | -45.56% | -21.56% |
| 5-year return | +3.94% | -83.28% |
| P/E ratio (TTM) | 8.23 | — |
| Forward P/E | 15.06 | — |
| EPS (TTM) | $0.64 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $9.68M |
| Revenue growth (YoY) | +617.03% | -92.83% |
| Net income (latest FY) | $163.06M | $-244.09M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -2216.44% |
| Net margin | 52.31% | -2520.57% |
| 52-week high | $13.02 | $11.80 |
| 52-week low | $4.47 | $7.70 |
| Distance from 52-week high | -59.52% | -30.34% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +161.86% | +160.34% |
| Average volume | 1.44M | 487.91K |
| Shares outstanding | 79.54M | 51.35M |
| Employees | 191 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRTA has outperformed CRMD by 24.0 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -2520.6 cents for Prothena.
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs -92.83%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
CRMD vs PRTA FAQ
Which is bigger, CorMedix or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $422.10M compared with $419.16M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or PRTA?
PRTA returned -21.56% over the past 12 months, compared with -45.56% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.